| Literature DB >> 24607843 |
Burkhard Kneitz1, Markus Krebs, Charis Kalogirou, Maria Schubert, Steven Joniau, Hein van Poppel, Evelyne Lerut, Susanne Kneitz, Claus Jürgen Scholz, Philipp Ströbel, Manfred Gessler, Hubertus Riedmiller, Martin Spahn.
Abstract
A lack of reliably informative biomarkers to distinguish indolent and lethal prostate cancer is one reason this disease is overtreated. miR-221 has been suggested as a biomarker in high-risk prostate cancer, but there is insufficient evidence of its potential utility. Here we report that miR-221 is an independent predictor for cancer-related death, extending and validating earlier findings. By mechanistic investigations we showed that miR-221 regulates cell growth, invasiveness, and apoptosis in prostate cancer at least partially via STAT1/STAT3-mediated activation of the JAK/STAT signaling pathway. miR-221 directly inhibits the expression of SOCS3 and IRF2, two oncogenes that negatively regulate this signaling pathway. miR-221 expression sensitized prostate cancer cells for IFN-γ-mediated growth inhibition. Our findings suggest that miR-221 offers a novel prognostic biomarker and therapeutic target in high-risk prostate cancer. ©2014 AACR.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24607843 DOI: 10.1158/0008-5472.CAN-13-1606
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701